Remove Hospitals Remove Insurance Coverage and Processing Remove Magazine
article thumbnail

UK enacts law to decentralise manufacture of personalised treatments

Pharmaceutical Technology

Find out more Introduced by the Medicines and Healthcare products Regulatory Agency (MHRA), it will allow patients to receive personalised treatments made at their hospital, clinic or near their homes. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

article thumbnail

Apertura signs multiple licensing agreements for TfR1 CapX tech

Pharmaceutical Technology

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. The undisclosed biotech company’s option agreement with Apertura will investigate the potential of TfR1 CapX in conjunction with its payloads aimed at treating CNS disorders. The specific terms of the agreement remain confidential.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Harbour BioMed partners Otsuka on new T-cell therapy

Pharmaceutical Technology

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. In 2024, Otsuka announced the acquisition of US-based Jnana Therapeutics in a deal worth up to $1.1bn. Editorial content is independently produced and follows the highest standards of journalistic integrity.

article thumbnail

ViroCell and AvenCell to advance allogeneic CAR-T therapy manufacture

Pharmaceutical Technology

By incorporating a cell line from AvenCell into good manufacturing practice processes, ViroCell met the challenge of delivering a high-yield vector within the required timeframe. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Topic sponsors are not involved in the creation of editorial content.

article thumbnail

Sartorius to invest $3m for minority share in biotech start-up Nanotein

Pharmaceutical Technology

Nanotein Technologies co-founder and CEO Curtis Hodge said: “Nanotein’s soluble activators are designed to improve cell therapy expansion by enhancing the quality and quantity of T cells and providing a feeder-free soluble activator for NK cell activation and expansion, addressing critical challenges in the manufacturing process.”

article thumbnail

Porton Advanced and EVA Pharma collaborate for CAR T-cell therapies

Pharmaceutical Technology

Porton Advanced will apply its knowledge in viral vector technology and CAR-T cell therapy process development to enhance EVA Pharma’s mission to provide safe, effective, and scalable cancer treatments. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

article thumbnail

Ethris and Thermo Fisher partner on mRNA solutions

Pharmaceutical Technology

These platforms are designed for safe drug production while allowing scaleable manufacturing processes. mRNA vaccine coverage on Pharmaceutical Technology (or Clinical Trials Arena) is supported by Trilink. The trial data indicated dose-dependent protein production at the site without systemic bioavailability. “By